Hussman Strategic Advisors Inc. Sells 63,000 Shares of Progyny, Inc. (NASDAQ:PGNY)

Hussman Strategic Advisors Inc. lessened its stake in Progyny, Inc. (NASDAQ:PGNY) by 60.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 42,000 shares of the company’s stock after selling 63,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Progyny were worth $724,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PGNY. GAMMA Investing LLC lifted its stake in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after buying an additional 1,246 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares during the period. Caitlin John LLC lifted its stake in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after buying an additional 3,183 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Progyny in the third quarter valued at about $77,000. Finally, KBC Group NV lifted its stake in shares of Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after buying an additional 2,140 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Trading Up 0.8 %

NASDAQ PGNY opened at $23.88 on Friday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 41.17, a PEG ratio of 2.28 and a beta of 1.34. The company has a 50 day moving average of $19.67 and a 200-day moving average of $18.68. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $40.89.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Barclays reduced their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Canaccord Genuity Group cut their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Bank of America raised their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Finally, Truist Financial restated a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Hold” and a consensus price target of $25.83.

Insider Transactions at Progyny

In other news, CEO Peter Anevski acquired 209,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.